Screening individuals for lung cancer with low-dose CT on a nonrisk basis is associated with a marked reduction in lung cancer mortality and better overall survival, reveals Chinese data.

CLEVELAND, March 10, 2026 /PRNewswire/ -- Oncologists currently have limited tools to predict which lung cancer patients will benefit from immunotherapy. The publication of a multi-institutional study ...

Dr Jonathan Goldman of the University of California, Los Angeles, highlights key abstracts in early-stage NSCLC from ASCO 2025. Dr Goldman begins with updated results from CheckMate 816, comparing ...

In 2025, ESMO Open published 6-year data for the CheckMate 9LA trial, which continued to show overall survival benefits for patients with metastatic non–small cell lung cancer (NSCLC) who had received ...

Lung cancer is cancer that starts in your lungs. It is the leading cause of cancer death among men and women. Finding lung cancer early before it spreads improves your chances of beating the disease.

Physiologically Based Pharmacokinetic Model to Assess the Drug-Drug-Gene Interaction Potential of Belzutifan in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors A total of 14,177 patients were ...

ORR 35.8% overall, 37.5% in second-/third-line, and 47.1% in light/nonsmokers, with median DOR not reached in key subsets.

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...